Association study of a brain-derived neurotrophic factor polymorphism and short-term antidepressant response in major depressive disorders | Zendy

Eugene Lin | Zendy

Open Access

Association study of a brain-derived neurotrophic factor polymorphism and short-term antidepressant response in major depressive disorders

Author(s) -

Eugene Lin

Publication year - 2008

Publication title -

pharmacogenomics and personalized medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.845

H-Index - 28

ISSN - 1178-7066

DOI - 10.2147/pgpm.s4116

Subject(s) - venlafaxine , single nucleotide polymorphism , major depressive disorder , antidepressant , medicine , brain derived neurotrophic factor , snp , neurotrophic factors , oncology , polymorphism (computer science) , psychiatry , bioinformatics , genetics , gene , genotype , biology , receptor , amygdala , hippocampus

Major depressive disorder (MDD) is one of the most common mental disorders worldwide. Single nucleotide polymorphisms (SNPs) can be used in clinical association studies to determine the contribution of genes to drug efficacy. A common SNP in the brain-derived neurotrophic factor (BDNF) gene, a methionine (Met) substitution for valine (Val) at codon 66 (Val66Met), is a candidate SNP for influencing antidepressant treatment outcome. In this study, our goal was to determine the relationship between the Val66Met polymorphism in the BDNF gene and the rapid antidepressant response to venlafaxine in a Taiwanese population with MDD. Overall, the BDNF Val66Met polymorphism was found not to be associated with short-term venlafaxine treatment outcome. However, the BDNF Val66Met polymorphism showed a trend to be associated with rapid venlafaxine treatment response in female patients. Future research with independent replication in large sample sizes is needed to confirm the role of the BDNF Val66Met polymorphism identified in this study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research